Completed PHASE2 INTERVENTIONAL 5-arm NCT01563029

A Dose-ranging Study of Fluticasone Furoate (FF)

A Dose-ranging Study of Fluticasone Furoate (FF) Inhalation Powder in Children Aged 5-11 Years With Asthma

Sponsor: GlaxoSmithKline

Conditions Asthma

Interventions Fluticasone Furoate Fluticasone Propionate Placebo

Updated 9 times since 2017 Last updated: Apr 25, 2017 Started: Mar 28, 2012 Primary completion: Sep 24, 2014 Completion: Sep 24, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01563029, this PHASE2 trial focuses on Asthma and remains completed. Sponsored by GlaxoSmithKline, it has been updated 9 times since 2012, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

9 versions recorded

Oct 2025 — Present [monthly]

Completed PHASE2
Sep 2025 — Oct 2025 [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2

▶ Show 4 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jul 2017 — Jun 2018 [monthly]

Completed PHASE2
Feb 2017 — Jul 2017 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Mar 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

GlaxoSmithKline

Data source: GlaxoSmithKline

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Austin, United States , Aventura, United States , Berchtesgaden, Germany , Berlin, Germany , Bialystok, Poland , Blagoveshchensk, Russia , Bochum, Germany , Bydgoszcz, Poland , Canton, United States , CapeTown, South Africa and 107 more locations